Key result
Post-ACS oral combination lipid therapy sustains LDL-C <55 mg/dL in ~51% of patients at 36 months.
Why the study?
Real-world attainment of LDL-C <55 mg/dL after ACS remains suboptimal despite strong guideline recommendations. Whether systematic early reassessment combined with predominant oral combination lipid-lowering therapy can achieve durable target control was uncertain.
Does a structured intensive oral combination lipid-lowering therapy strategy with early reassessment improve longitudinal LDL-C <55 mg/dL goal attainment in post-ACS patients undergoing PCI?
Cohort
No
Does a structured intensive oral combination lipid-lowering therapy strategy with early reassessment improve longitudinal LDL-C <55 mg/dL goal attainment in post-ACS patients undergoing PCI?
Structured early reassessment with predominant oral combination lipid-lowering therapy achieves high initial LDL-C <55 mg/dL attainment post-ACS, but treatment de-intensification after the first year leads to a substantial decline in long-term target maintenance.
Early combination LLT may aid short-term LDL-C control post-ACS; leaves open strategies for sustained long-term attainment.
Background Despite strong recommendations from the European Society of Cardiology / European Atherosclerosis Society for low-density lipoprotein cholesterol (LDL-C) <55 mg/dL after acute coronary syndrome (ACS), real-world attainment remains suboptimal. Whether systematic early reassessment, combined with the predominant use of oral combination lipid-lowering therapy (LLT), can achieve durable target control is uncertain. Purpose To evaluate longitudinal LDL-C goal attainment and the impact of sustained combination therapy in a consecutive post-ACS percutaneous coronary intervention (PCI) cohort managed under a structured intensive lipid strategy. Methods All consecutive ACS patients undergoing PCI between October 2022 and January 2026 were included. Institutional policy mandated intensive LLT at discharge, favouring dual or predominantly triple oral therapy targeting LDL-C <55 mg/dL, with repeat lipid testing encouraged every 3–6 months. Predefined follow-up intervals were analysed up to 36 months. The proportions achieving LDL-C <55 mg/dL and receiving combination therapy were assessed longitudinally. Results At 1 month, 93.8% of patients received combination therapy, and 78.6% achieved LDL-C <55 mg/dL. Goal attainment remained high during the first year (77–79%) while combination therapy use exceeded 86%. Beyond 12 months, a progressive reduction in combination therapy (to ~74% at 18–24 months) was paralleled by declining LDL-C target achievement (74.4% at 18 months; 67.7% at 24 months). At 36 months, LDL-C <55 mg/dL was achieved in 51.1% of patients. Temporal reductions in treatment intensity were consistently associated with a decline in LDL-C target durability. Conclusion In a real-world ACS population, structured early reassessment combined with predominant oral combination therapy achieved high guideline-recommended initial LDL-C goal attainment. However, therapeutic de-intensification beyond the first year undermined long-term maintenance of lipid targets. Sustained combination therapy and systematic follow-up are essential to prevent late loss of control.
No takes yet. Share an insight, caveat, or question.
Mahajan et al. (2026) conducted a cohort in Acute coronary syndrome undergoing percutaneous coronary intervention. Structured intensive lipid-lowering strategy with predominant oral combination therapy was evaluated on Longitudinal achievement of LDL-C <55 mg/dL. Oral combination lipid-lowering therapy after ACS achieved LDL-C <55 mg/dL in 78.6% at 1 month, declining to 51.1% at 36 months alongside reduced combination therapy use.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: